Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
about
Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysisThe ubiquitin-proteasome system and cardiovascular diseaseTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesThe ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathyMyosin light chain phosphorylation is critical for adaptation to cardiac stress.The ubiquitin proteasome system and myocardial ischemiaOverexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibitionToxicology of chemically modified graphene-based materials for medical application.Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.Proteasome inhibitors and cardiac cell growthThe ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective.The ubiquitin-proteasome system in myocardial ischaemia and preconditioning.Atrogin-1 deficiency promotes cardiomyopathy and premature death via impaired autophagy.Autophagy and the ubiquitin-proteasome system in cardiac dysfunction.Screening of potential molecular targets for colorectal cancer therapy.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Cardiotoxicity of the anticancer therapeutic agent bortezomib.The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts.The ubiquitin-proteasome system and assays to determine responses to inhibitors.Perturbation of cullin deneddylation via conditional Csn8 ablation impairs the ubiquitin-proteasome system and causes cardiomyocyte necrosis and dilated cardiomyopathy in mice.Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.Proteome dynamics and proteome function of cardiac 19S proteasomesCardiotoxicity of molecularly targeted agentsA phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaUnderstanding proteasome assembly and regulation: importance to cardiovascular medicine.Breaking down protein degradation mechanisms in cardiac muscle.Protein quality control and degradation in cardiomyocytes.Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissuesA therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis.Regulation of acetylation restores proteolytic function of diseased myocardium in mouse and human.Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.Bortezomib-induced Severe Congestive Heart Failure.Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern?The role of the proteasome in heart diseaseHeterogeneous cardiac proteasomes: mandated by diverse substrates?Biological drugs: classic adverse effects and new clinical evidences.Severe heart failure after bortezomib treatment in a patient with multiple myeloma: a case report and review of the literature.
P2860
Q26991817-38ECE816-2431-4C13-A636-371E2EBA0FF9Q27021582-BADA44D4-A316-4953-9153-50A54F7F156FQ27026951-59892733-94A1-45BE-BDE8-1917FCADEDC4Q28252486-44AB4068-9D4C-448C-B3D5-2FDAE375256EQ28277846-6D118FD9-5D24-44DB-BD45-B676582D30CEQ28280898-2CF5FEE4-303D-4C43-87B5-E5EECF763857Q28281770-95578E60-FF3A-4B99-B1BB-62BB984FCA7BQ30427860-34065DFE-A6DF-4A81-AFCB-024C93400D16Q33397376-56145CF4-433D-4F74-9927-5D299B5DB711Q33482818-413318E5-001C-4E14-AE30-0270CD3E3DCFQ33554490-845B4D0A-8541-49F1-ACEB-DBCA10DE338CQ33554497-B6C44318-D635-41DA-A802-1AED270E7A37Q33554506-B9212B5A-9E57-4983-B677-4086766F041AQ33685877-F5654164-D8FC-4C96-B0E5-4DE709F2ED5FQ33733547-3BCAAEE7-A957-4ADB-BB42-BDA5DB329646Q33735051-D943B36F-178C-476D-806F-D5FBA176C6C5Q33807542-A1310D11-4D88-4354-BAA8-D9CC4BE1CFEAQ33882390-DD098721-0D99-4618-8C48-2247FC2A99F6Q33919062-89AFF10E-BF20-4AD5-AEF6-9014E4543497Q34275603-EDAF6BDC-AFB6-4D28-84C1-627C4D76EB4BQ34347848-33B40A64-D94B-4756-87AC-3C823E8AF315Q34474447-63D2CD4E-A1C5-447D-8A02-143B783DDF57Q34893956-F6819777-C9CF-4DE8-99BE-407C4ACF4833Q34994354-342410EC-28E1-4352-9D81-9D0B5B2C5C9AQ35878459-45B7F728-8A9A-4668-9E39-7218B6351854Q36671445-47B1B41A-5233-4C78-A9B4-5712A4D744A4Q36740475-8878845A-4A02-431B-BA53-A10230ABFBC4Q36756282-0E899C49-40ED-4E26-B8DF-847ABF4CB5A5Q36952213-C6AA8F55-22F9-49D5-B581-F31165C6F3DFQ37080673-D785B9EF-7C1F-4E5F-9790-094072A5D7D7Q37124125-AEC16634-9D84-4B44-BDA9-6C35AABD85DBQ37247207-5F456616-D39A-40B2-A819-855B8BF9B114Q37389011-CC124756-7B79-4707-99CC-6E269D53E628Q37677121-7B7F85B4-EBF5-41EB-A134-CD52FB88513EQ37711394-369775DE-4001-4666-A6F6-FD03F5FB41FFQ37723147-55E59568-C8C4-4B99-8273-9428C66DAB48Q37788836-3CFE8791-F6D7-42CE-9D71-F840940BB9EBQ37864471-2DC63107-420C-4E49-A1EE-268D13B3DA18Q38015746-17E938D3-3600-4307-8A44-9C7F675ED959Q38042295-940B83F0-0DDE-4138-8A70-8A973565BB1C
P2860
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Severe reversible cardiac fail ...... cancer patient: a case report.
@ast
Severe reversible cardiac fail ...... cancer patient: a case report.
@en
type
label
Severe reversible cardiac fail ...... cancer patient: a case report.
@ast
Severe reversible cardiac fail ...... cancer patient: a case report.
@en
prefLabel
Severe reversible cardiac fail ...... cancer patient: a case report.
@ast
Severe reversible cardiac fail ...... cancer patient: a case report.
@en
P2860
P356
P1433
P1476
Severe reversible cardiac fail ...... cancer patient: a case report.
@en
P2093
Jens Voortman
P2860
P2888
P356
10.1186/1471-2407-6-129
P407
P577
2006-05-11T00:00:00Z
P5875
P6179
1011079645